Maze Therapeutics (MAZE) Income from Continuing Operations (2024 - 2026)

Maze Therapeutics has disclosed Income from Continuing Operations across 3 years of filings, most recently posting 24208000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 24208000.0, up 26.16% year-over-year; the trailing twelve-month figure through Mar 2026 was 122542000.0 (down 336.18% YoY), and the FY2025 annual result was 131120000.0, down 351.17% from the prior year.
• Income from Continuing Operations came in at 24208000.0 for Q1 2026 at Maze Therapeutics, up from 34568000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 139056000.0 in Q2 2024 to a low of 34568000.0 in Q4 2025.
• The 3-year median for Income from Continuing Operations is 29654000.0 (2024), against an average of 10932222.22.
• Across the five-year window, Income from Continuing Operations slumped 124.22% in 2025 and rose 26.16% in 2026, its largest moves.
• Maze Therapeutics' Income from Continuing Operations stood at 29654000.0 in 2024, then retreated by 16.57% to 34568000.0 in 2025, then increased by 29.97% to 24208000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 24208000.0 (Q1 2026), 34568000.0 (Q4 2025), and 30087000.0 (Q3 2025), per Business Quant data.